Published in Immunol Rev on July 01, 2010
Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol (2012) 2.79
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76
Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes. Nat Immunol (2011) 2.38
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell (2016) 2.28
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature (2016) 1.90
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.65
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol (2012) 1.46
Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat Commun (2012) 1.11
mTOR and metabolic pathways in T cell quiescence and functional activation. Semin Immunol (2013) 1.11
Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One (2011) 1.11
Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. Proc Natl Acad Sci U S A (2014) 0.99
IL4I1: an inhibitor of the CD8⁺ antitumor T-cell response in vivo. Eur J Immunol (2011) 0.98
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.95
Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation. Eur J Immunol (2013) 0.95
Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 0.95
Amino acid auxotrophy as a system of immunological control nodes. Nat Immunol (2015) 0.92
Tumor-dependent increase of serum amino acid levels in breast cancer patients has diagnostic potential and correlates with molecular tumor subtypes. J Transl Med (2013) 0.92
Terminating the immune response. Immunol Rev (2010) 0.90
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Rat mesenchymal stromal cells inhibit T cell proliferation but not cytokine production through inducible nitric oxide synthase. Front Immunol (2012) 0.86
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells. Immunity (2017) 0.85
Cofilin: a redox sensitive mediator of actin dynamics during T-cell activation and migration. Immunol Rev (2013) 0.84
The role of indoleamine 2,3-dioxygenase in LP-BPM5 murine retroviral disease progression. Virol J (2013) 0.83
Vascular endothelial growth factor-A enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation. Mem Inst Oswaldo Cruz (2013) 0.83
Tolerogenic pDCs: spotlight on Foxo3. J Clin Invest (2011) 0.82
Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem (2015) 0.81
T-cell energy metabolism as a controller of cell fate in transplantation. Curr Opin Organ Transplant (2015) 0.81
Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. J Immunol (2015) 0.81
Antibacterial properties of the mammalian L-amino acid oxidase IL4I1. PLoS One (2013) 0.80
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion. PLoS One (2013) 0.78
Metabolomic Analyses of Leishmania Reveal Multiple Species Differences and Large Differences in Amino Acid Metabolism. PLoS One (2015) 0.77
Serum arginase, a biomarker of treatment efficacy in human African trypanosomiasis. J Clin Microbiol (2013) 0.77
Biology of Bony Fish Macrophages. Biology (Basel) (2015) 0.77
Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells. Neuropharmacology (2015) 0.77
Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. Front Immunol (2016) 0.76
Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses. PLoS One (2013) 0.75
Leucine Metabolism in T Cell Activation: mTOR Signaling and Beyond. Adv Nutr (2016) 0.75
Haemato-biochemical disorders associated with nodavirus like-agent in adult leaping mullet Liza saliens (Risso, 1810) in the Caspian Sea. Virusdisease (2015) 0.75
An N-nitrosation reactivity-based two-photon fluorescent probe for the specific in situ detection of nitric oxide. Chem Sci (2017) 0.75
Fetal dendritic cells give mum a break. Immunol Cell Biol (2017) 0.75
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol (2005) 6.05
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol (2010) 4.62
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol (2002) 3.56
Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol (2010) 3.18
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51
Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci U S A (2005) 2.49
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med (2011) 2.06
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03
Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87
Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci (2014) 1.69
Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol (2009) 1.68
Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe (2013) 1.62
Part I: Vaccines for solid tumours. Lancet Oncol (2004) 1.61
Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep (2012) 1.59
Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood (2005) 1.56
Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev (2007) 1.55
Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood (2011) 1.47
Role of arginine metabolism in immunity and immunopathology. Immunobiology (2007) 1.33
Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett (2008) 1.31
Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res (2005) 1.28
Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol (2011) 1.25
Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood (2009) 1.20
Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion. Eur J Immunol (2014) 1.08
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 1.07
Exocytosis of azurophil and arginase 1-containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation. J Leukoc Biol (2011) 1.07
miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity (2013) 1.07
Modulation of human T-cell functions by reactive nitrogen species. Eur J Immunol (2011) 1.03
Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol (2011) 1.02
IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine (2010) 1.02
Myeloid cell diversification and complexity: an old concept with new turns in oncology. Cancer Metastasis Rev (2011) 1.01
Retracted High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res (2012) 1.01
In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res (2009) 1.00
Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res (2008) 0.99
The pros and cons of chemokines in tumor immunology. Trends Immunol (2012) 0.99
Cancer vaccines: pessimism in check. Nat Med (2004) 0.97
Metabolic mechanisms of cancer-induced inhibition of immune responses. Semin Cancer Biol (2007) 0.97
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.95
Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid (2007) 0.95
Measurement of myeloid cell immune suppressive activity. Curr Protoc Immunol (2010) 0.94
Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes. Cancer Res (2004) 0.90
Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol (2010) 0.89
Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. Blood (2013) 0.89
Role of microRNAs in HTLV-1 infection and transformation. Mol Aspects Med (2010) 0.85
Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis (2009) 0.84
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. J Virol (2014) 0.83
Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. Neoplasia (2012) 0.83
Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. BMC Cell Biol (2012) 0.83
Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol (2009) 0.82
L-glutamine is a key parameter in the immunosuppression phenomenon. Biochem Biophys Res Commun (2012) 0.82
Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Biomatter (2014) 0.81
Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom (2014) 0.80
The transcriptional response in human umbilical vein endothelial cells exposed to insulin: a dynamic gene expression approach. PLoS One (2010) 0.78
Myeloid-derived suppressor cells exhibit two bioenergetic steady-states in vitro. J Biotechnol (2011) 0.78
Smoothing T cell roads to the tumor: Chemokine post-translational regulation. Oncoimmunology (2012) 0.77
CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response. Cancer Immunol Immunother (2004) 0.77
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell (2016) 0.76
Nitric oxide affects immune cells bioenergetics: long-term effects of nitric-oxide derivatives on leukaemic Jurkat cell metabolism. Immunobiology (2012) 0.75
Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. Xenotransplantation (2003) 0.75
Tumor-Induced Myeloid-Derived Suppressor Cells. Microbiol Spectr (2016) 0.75